169 related articles for article (PubMed ID: 28619621)
1. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Valmary-Degano S; Colpart P; Villeneuve L; Monnien F; M'Hamdi L; Lang Averous G; Capovilla M; Bibeau F; Laverriere MH; Verriele-Beurrier V; Ben Rejeb H; Dartigues P; Hommell-Fontaine J; Gilly FN; Isaac S; Mery E;
Eur J Surg Oncol; 2017 Oct; 43(10):1915-1923. PubMed ID: 28619621
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
3. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Sun WY; Lee YK; Koo JS
J Transl Med; 2016 Jun; 14(1):173. PubMed ID: 27286842
[TBL] [Abstract][Full Text] [Related]
4. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
6. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
7. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
Schats KA; Van Vré EA; De Schepper S; Boeckx C; Schrijvers DM; Waelput W; Fransen E; Vanden Bempt I; Neyns B; De Meester I; Kockx MM
Histopathology; 2017 Jan; 70(2):253-263. PubMed ID: 27496355
[TBL] [Abstract][Full Text] [Related]
8. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
[TBL] [Abstract][Full Text] [Related]
9. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
10. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Keller MD; Neppl C; Irmak Y; Hall SR; Schmid RA; Langer R; Berezowska S
Mod Pathol; 2018 Jan; 31(1):101-110. PubMed ID: 28884747
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
13. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
[TBL] [Abstract][Full Text] [Related]
14. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
15. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX
Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
[TBL] [Abstract][Full Text] [Related]
17. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
Takada K; Toyokawa G; Okamoto T; Akamine T; Takamori S; Katsura M; Fujishita T; Shoji F; Oda Y; Maehara Y
Anticancer Res; 2016 Jul; 36(7):3409-12. PubMed ID: 27354600
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
[TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.
Benzerdjeb N; Dartigues P; Kepenekian V; Valmary-Degano S; Mery E; Avérous G; Chevallier A; Laverriere MH; Villa I; Harou O; Sallé FG; Villeneuve L; Glehen O; Isaac S; Hommell-Fontaine J; Bibeau F;
Virchows Arch; 2021 Oct; 479(4):765-772. PubMed ID: 33855595
[TBL] [Abstract][Full Text] [Related]
20. Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients.
Yoneta D; Kato J; Kamiya T; Horimoto K; Sato S; Sawada M; Minowa T; Hida T; Sugita S; Uhara H
Int J Clin Oncol; 2022 Aug; 27(8):1364-1371. PubMed ID: 35650364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
